Abstract
The neuropeptide, galanin, and its receptors are localized in the cholinergic basal forebrain and its projection areas in mammalian brain. Centrally administered galanin inhibits acetylcholine release in the rat ventral hippocampus, and produces deficits in learning and memory tasks. In Alzheimer's disease, galanin is overexpressed in terminals innervating the nucleus basalis of Meynert cell bodies. Selective galanin receptor antagonists provide a novel approach for increasing cholinergic function, as a potential adjunct to the clinical treatment of dementias.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2185-2199 |
| Number of pages | 15 |
| Journal | Life Sciences |
| Volume | 58 |
| Issue number | 24 |
| DOIs | |
| State | Published - May 10 1996 |
| Externally published | Yes |
Keywords
- Acetylcholine
- Alzheimer's disease
- Galanin
- Learning and memory
- Neuropeptide
- Neurotransmitter release
ASJC Scopus subject areas
- Pharmacology